Fiche centre
The First Affiliated Hospital of Guangzhou Medical University
Guangzhou — China
Essais liés6clinical trials
VilleGuangzhoulocalisation
PaysChinalocalisation
SourcelocaleCSV/MySQL
Informations
centreSynchronisé depuis ClinicalTrials.gov — NCT04619472
Essais cliniques associés
6| Molécule | Indication / population | Phase | NCT | Titre | Statut |
|---|---|---|---|---|---|
| Adagrasib | Cancer | Phase 2/3 | NCT04613596 | Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7 | RECRUITING |
| Nivolumab | Cancer | Phase 3 | NCT06561386 | RELATIVITY1093 — A Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy for Stage IV/Recurrent Non-squamous Non-small Cell Lung Cancer With PD-L1 Expression ≥ 1% | RECRUITING |
| Chronotherapy-based individualized low-morning high-evening tacrolimus dosing | Maladie rénale chronique | Phase 4 | NCT07877103 | Study on the Safety and Efficacy of a Time-of-Day-Based Individualized Tacrolimus Dosing Regimen in Kidney Transplant Recipients | NOT_YET_RECRUITING |
| Pulmonary Radiofrequency Ablation System and the Disposable Pulmonary Radiofrequency Ablation Catheter | Cancer | Non applicable | NCT04619472 | BRONC-RFⅡ — Safety and Effectiveness of Radiofrequency Ablation System in the Treatment of Peripheral Lung Tumors | COMPLETED |
| Adagrasib | Cancer | Phase 3 | NCT06875310 | A Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4) | RECRUITING |
| Prasinezumab | Parkinson | Phase 3 | NCT07174310 | PARAISO — A Study to Evaluate the Efficacy and Safety of Intravenous (IV) Prasinezumab in Participants With Early-Stage Parkinson's Disease | RECRUITING |